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Down syndromeThe regulation of mitochondrial biogenesis is under the control of nuclear genes including the master Mitochon-
drial Transcription Factor A (TFAM). Recent evidence suggests that the expression of TFAM is regulated by
microRNAs (miRNAs) in various cellular contexts. Here, we show that hsa-miR-155-5p, a prominent miRNA
encoded in chromosome 21, controls the expression of TFAM at the post-transcriptional level. In human ﬁbro-
blasts derived from a diploid donor, downregulation of TFAM by hsa-miR-155-5p decreased mitochondrial DNA
(mtDNA) content. In contrast, downregulation of TFAM by hsa-miR-155-5p did not decrease mtDNA content in
ﬁbroblasts derived from adonorwithDown syndrome (DS, trisomy21). In line, downregulation ofmitochondrial
TFAM levels through hsa-miR-155-5p decreased mitochondrial mass in diploid ﬁbroblasts but not in trisomic
cells. Due to the prevalence of mitochondrial dysfunction and cardiac abnormalities in subjects with DS, we ex-
amined the presence of potential associations between hsa-miR-155-5p and TFAM expression in heart samples
from donors with and without DS. There were signiﬁcant negative associations between hsa-miR-155-5p and
TFAM expression in heart samples from donors with and without DS. These results suggest that regulation of
TFAM by hsa-miR-155-5p impacts mitochondrial biogenesis in the diploid setting but not in the DS setting.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
TFAM (Mitochondrial Transcription Factor A) is a nucleus-encoded
protein that plays a pivotal role in the transcription and maintenance
of mitochondrial DNA (mtDNA) [1,2]. TFAM regulates mtDNA copy
number and mitochondrial biogenesis [3–5]. Reports have shown that
the expression of TFAM is in part regulated by speciﬁc microRNAs
(miRNAs). miRNAs are small noncoding RNAs that control the expres-
sion of target genes through mechanisms involving the suppression of
mRNA translation or the stimulation of mRNA degradation [6]. For ex-
ample, miR-23b down-regulates TFAM in glioma cells which in turn
leads to inhibition of cell proliferation, cell cycle progression, migration
and colony formation [7]. Yamamoto et al. have shown that miR-494
regulates mitochondrial biogenesis in skeletal muscle through TFAM
and Forkhead box j3 [8]. A recent study by Yao et al. identiﬁed miR-
200a as a regulator of TFAM expression and mtDNA copy number in
breast cancer cells [9].
Hsa-miR-155, a multifunctional microRNA encoded by chromosome
21, is involved in various biological and pathological processes including
immunity and inﬂammation [10,11]. For example, the overexpression
of hsa-miR-155 in damaged hearts after viral myocarditis has beeneutical Sciences, University at
Hall, Buffalo, NY 14214-8033,linked to adverse cardiac immune activation [12]. The chromosomal lo-
cation of hsa-miR-155 has motivated studies to elucidate its potential
contribution to the complex pathophysiology of Down syndrome (DS,
trisomy 21) [13]. Recently, we quantitated the expression of hsa-miR-
155 in heart tissue and found no differences between samples from do-
nors with andwithout DS [14]. We postulated that inter-individual var-
iability together with factors that impact global gene expression in
trisomy 21 (e.g., chromatin accessibility) may offset the expected
gene-dosage increase for cardiac hsa-miR-155 expression in the DS set-
ting [15].
Mitochondrial dysfunction has been noted as a possible contributor
to the DS phenotype [16]. For example, Coskun et al. described de-
creased mtDNA in brain tissue from donors with DS and dementia
[17]. We have documented an average 33% decrease in cardiac mtDNA
content in samples from donors with DS in comparison to age-
matched samples from donors without DS; although the trend towards
decreased cardiac mtDNA content did not reach statistical signiﬁcance
(P N 0.05), we speculated that subtle decreases in cardiac mtDNA may
have pathophysiological relevance in the context of DS [14]. Additional
lines of evidence formitochondrial dysfunction in DS include changes in
the expression of genes involved in the Krebs cycle and oxidative phos-
phorylation, and reductions in the activity of mitochondrial enzymes
[18–23]. Thus, the essential role of TFAM during maintenance of
mtDNA, the evidence in support of mitochondrial dysfunction in DS,
and the potential contribution of hsa-miR-155 to the DS phenotype
lead us to hypothesize that TFAM may be differentially regulated by
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test whether hsa-miR-155 regulates TFAM expression and mitochondri-
al biogenesis in cell lines derived from subjects with and without DS.
Complementary studies were performed to test for associations be-
tween TFAM and hsa-miR-155 expression in heart samples from donors
with and without DS.
2. Methods
2.1. Cell culture and reagents
CHO-K1 cells (Chinese hamster ovary-derived cell line, CCL-61)
were obtained from the American Type Culture Collection (Manassas,
VA). Fibroblast cell lines derived from donors with (GM01920) and
without DS (GM00323) were obtained from the Coriell Institute for
Medical Research (Camden, NJ). Cell culture reagents were purchased
from Life Technologies (Carlsbad, CA). Fibroblast cell lineswere routine-
ly cultured in T75 ﬂasks using DMEM medium. CHO-K1 cells were
grown in F12K medium. DMEM and F12K media were supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (Sigma-Aldrich, St.
Louis, MO), 100 U/mL penicillin, and 100 μg/mL streptomycin. Cultures
were grown and maintained at low passage numbers (n b 12) using
standard incubation conditions at 37 °C, 5% CO2, and 95% relative
humidity.
2.2. Constructs and site-directed mutagenesis
The microRNA mimic and hairpin inhibitor for hsa-miR-155-5p, as
well as mimic and inhibitor negative controls, were obtained from GE
Dharmacon (Lafayette, CO). The full-length TFAM 3′-UTR construct
was synthesized by OriGene (Rockville, MD). A 1078 bp TFAM 3′-UTR
fragment was cloned into a pMirTarget vector (OriGene) downstream
of the ﬁreﬂy luciferase gene. The QuikChange II XL-site-directed muta-
genesis kit (Agilent, Santa Clara, CA) was used to generate a construct
containing the 3′-UTR of TFAM with a mutated seed sequence for hsa-
miR-155-5p. The following primers were used for site-directed muta-
genesis: forward primer 5′-CCTTATATTATGGATCCAGGAGTTTCGTTT
TC-3′, and reverse primer 5′-GAAAACGAAACTCCTGGATCCATAATATAA
GG-3′ (the mutated bases are underlined). All constructs were veriﬁed
by DNA sequencing.
2.3. Transfections
Twenty four hours prior to transfections, CHO-K1 cells were plated
in 24-well plates. CHO-K1 cells were co-transfected with the TFAM 3′-
UTR or the mutant TFAM 3′-UTR (mutTFAM 3′-UTR) luciferase reporter
construct (50 ng) plus the internal control plasmid pRL-TK (5 ng) and
hsa-miR-155-5p miRNA mimic (5 nM), in the presence or absence of
the speciﬁc hsa-miR-155-5p inhibitor (50 nM), using DharmaFECT Duo
transfection reagent (GE Dharmacon). Identical concentrations of
miRNA mimic and inhibitor negative controls were used. Twenty four
hours post-transfection, cultures were washed once with phosphate-
buffered saline (PBS) solution; cellswere lysed in freshly diluted passive
lysis buffer (100 μl/well Promega,Madison,WI) by incubating the plates
at room temperature on a shaker at 200 rpm for 60 min. Luciferase re-
porter gene activities were determined with the Dual-Luciferase Re-
porter Assay System (Promega) per the manufacturer's instructions.
Light intensity was measured in a Synergy HT luminometer equipped
with proprietary software for data analysis (BioTek, Winooski, VT).
Corrected ﬁreﬂy luciferase activities were normalized to renilla lucifer-
ase activities and expressed as fold increases with respect to the values
obtained from control transfectionswithmiRNAmimic negative control
or the combination of miRNA mimic and inhibitor negative controls.
Twenty four hours prior transfections, ﬁbroblast cells (GM00323
and GM01920) were plated at 50% conﬂuence in 24-well plates. Cells
were co-transfected with hsa-miR-155-5p mimic or miRNA mimicnegative control (5 nM) in the presence or absence of speciﬁc hsa-
miR-155-5p inhibitor (50 nM) or inhibitor negative control using
DharmaFECT Duo transfection reagent. Cells were re-transfected after
48 h and collected 96 h after the initial transfection.
2.4. Isolation of cytosolic and mitochondrial protein
Cytosolic protein extraction was performed using the NE-PER Nu-
clear and Cytoplasmic Extraction Reagents kit (Pierce Biotechnology,
Rockford, IL) according to the manufacturer's instructions. Mito-
chondria were isolated from ﬁbroblast cells by differential centrifu-
gation with an isolation kit for cultured cells (Abcam, Cambridge,
MA, USA). Brieﬂy, samples were homogenized in isolation buffer on
ice, and the homogenates were centrifuged at 1000 g for 10 min at
4 °C. The supernatants were centrifuged at 12,000 g for 15 min at
4 °C to obtain the mitochondrial pellet. Protein concentrations
were determined with the bicinchoninic acid protein assay (Pierce).
2.5. TFAM content in mitochondria
Mitochondrial TFAM content was measured with the enzyme-linked
immunosorbent assay TFAM SimpleStep (Abcam) per themanufacturer's
instructions. Measurements were done in quadruplicates.
2.6. Mitochondrial citrate synthase activity
Mitochondrial citrate synthase activity was measured with an
immunocapture based assay (Abcam) by recording the color develop-
ment of 5-thio-2-nitrobenzoic acid (TNB) at 412 nm. Measurements
were done in triplicates.
2.7. Mitochondrial content in ﬁbroblasts
Mitotracker RED CMXRos (Life Technologies) was added to cell cul-
ture medium at a ﬁnal concentration of 20 nM. Cells were incubated for
30 min and ﬁxed in 4% paraformaldehyde for 15 min. Fixed cells were
washed 3 times with PBS (0.1 M) and mounted onto glass slides using
Fluorsave (Calbiochem, San Diego, CA). Cell images were captured
with a Zeiss Axiovert 200 ﬂuorescence microscope equipped with an
AxiocamMRC camera (Carl Zeiss, Jena, Germany). Cellular area andmi-
tochondrial content were measured with the ImageJ image analysis
software v1.43 (NIH, Bethesda,MD, http://rsb.info.nih.gov/ij/) and asso-
ciated plug-ins as reported [24].
2.8. Cell viability
The viability of transfected ﬁbroblast cells was assessed by recording
the reduction of 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT. Sigma). Brieﬂy, cells were plated in 96 well plates and
transfected as previously described. Then, 20 μL of MTT solution
(5 mg/mL) were added to each well followed by incubation at 37 °C
for 4 h. After incubation, the medium was removed and 100 μL of
DMSOwas added into each well. The plate was gently rotated on an or-
bital shaker for 10 min to dissolve the MTT precipitate. The absorbance
at 570 nmwas recorded with a Synergy HT microplate reader (BioTek).
Cellular viability was expressed as percentages relative to control
incubations.
2.9. Heart samples
The Institutional ReviewBoard of the State University of NewYork at
Buffalo approved this research. Heart samples from donors with (n =
11) and without DS (n= 32) were procured from The National Disease
Research Interchange (NDRI, funded by the National Center for Re-
search Resources), The Cooperative Human Tissue Network (CHTN,
funded by the National Cancer Institute), and the National Institute of
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Themain demographics fromdonorswith- andwithout-DS are summa-
rized in supplemental Table 1. The postmortem to tissue recovery inter-
val was≤10 h. Samples (2–20 g, myocardium, left ventricle only) were
frozen immediately after recovery and stored in liquid nitrogen until
further processing. DS status (yes/no) was obtained from anonymous
medical records and conﬁrmed by comparative array hybridizations as
described [14,25,26]. High quality RNA was isolated with an automatic
QuickGene-810 puriﬁcation system (Autogen/FujiFilm, Holliston, MA).
Purity and integrity of the RNA templates was assessed by measuring
A260/A280 ratio and by gel electrophoresis in denaturing conditions fol-
lowing MIQE guidelines [27].2.10. Quantiﬁcation of mtDNA content and hsa-miR-155-5p expression
mtDNA content and the expression of hsa-miR-155-5p in the col-
lection of heart samples from donors with and without DS have been
recently reported by us [14]. mtDNA content in cultured cells was
measured with a qRT-PCR based on the ampliﬁcation of the mito-
chondrial gene MT-ND1 and the nuclear gene 18S rRNA as reported
[14]. The expression of hsa-miR-155-5p in cultured cells was mea-
sured by qRT-PCR with speciﬁc primers as reported [14].2.11. Quantiﬁcation of TFAM mRNA expression
TFAM mRNA expression was analyzed by qRT-PCR with speciﬁc
primers (TFAMforward: 5′-GCGCTCCCCCTTCAGTTTTG-3′; TFAMreverse:
5′-GTTTTTGCATCTGGGTTCTGAGC-3′). Brieﬂy, total RNA (2.5 ng)
was reverse transcribed and ampliﬁed with one-step QuantiTect
SYBR Green RT-PCR kits (Qiagen, Venlo, The Netherlands). TFAM
and ACTB (reference gene, ACTBforward: 5′-GGACTTCGAGCAAGAGAT
GG-3′, and ACTBreverse: 5′-AGCACTGTGTTGGCGTACAG-3′) were am-
pliﬁed in parallel in an iQ5 thermal cycler (Bio-Rad) with the follow-
ing cycling parameters: 50 °C for 30 min (reverse transcription),
95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s, 56 °C for
30 s and 72 °C for 30 s. Calibration curves were prepared to analyze
linearity (r2 N 0.98) and PCR efﬁciency for the ampliﬁcation of
TFAM (efﬁciency: 101%) and ACTB (efﬁciency: 97%). For each sample,
the averaged Ct values for TFAM were normalized against the aver-
aged Ct values for ACTB using the dCt method [28]. The expression
of TFAM in individual heart samples was expressed relative to the av-
eraged expression of TFAM in the group of heart samples from donors
without DS (n = 32), which was assigned an arbitrary value of 1.0.2.12. Bioinformatics
The full-length sequence of human TFAM 3′-UTR (NCBI Reference
Sequence: NM_003201.1) was retrieved from Entrez (http://www.
ncbi.nlm.nih.gov/Entrez/). The RNAhybrid prediction tool was used to
identify the potential binding site for hsa-miR-155 in TFAM 3′-UTR [29].2.13. Data analysis
Statistics were computed with Excel 2013 (Microsoft Ofﬁce;
Microsoft, Redmond, WA) and GraphPad Prism version 4.03
(GraphPad Software Inc., La Jolla, CA). The Kolmogorov–Smirnov
test was used to analyze the normality of datasets. The Student's t
test was used to compare group means. Spearman's rank correlation
coefﬁcient was used for the correlation analysis of non-normally dis-
tributed data. Data are expressed as the mean ± standard deviation
(SD). Differences between means were considered to be signiﬁcant
at P b 0.05.3. Results
3.1. Hsa-miR-155-5p binds to TFAM
Computational screenings with the RNAhybrid prediction tool
were performed to pinpoint potential interactions between hsa-
miR-155 and the 3′-UTR of TFAM. A candidate region in TFAM
(NM_003201) located between nucleotides 1477 and 1495 showed an
energetically favorable free energy value (ΔΔG) of−18.7 Kcal/mol for
the biding of hsa-miR-155-5p (Fig. 1A). Next, we tested whether hsa-
miR-155-5p interacts with TFAM by performing luciferase assays in
CHO-K1 cells co-transfected with a reporter plasmid containing the
3′-UTR of TFAM or the mutant version (mutTFAM 3′-UTR) and hsa-
miR-155-5p. The co-transfection of hsa-miR-155-5p decreased the lucif-
erase activity of the TFAM 3′-UTR reporter construct in comparison to
control co-transfections (P b 0.001, Fig. 1B). The luciferase activity of
the TFAM 3′-UTR construct was rescued by co-transfection with a spe-
ciﬁc hairpin inhibitor for hsa-miR-155-5p (Fig. 1B). Moreover, hsa-
miR-155-5p-mediated repression of luciferase activity was abolished
when a mutation was introduced in two adjacent nucleotides within
the seed region of hsa-miR-155-5p (Fig. 1C).
3.2. Effect of hsa-miR-155-5p on TFAMmRNA expression andmtDNA content
in ﬁbroblast cell lines from donors with and without Down syndrome
Basal TFAMmRNA expression was signiﬁcantly lower in the DS cell
line than in the non-DS cell line under standard cell culture conditions
(TFAM mRNADS: 0.65 ± 0.27 relative fold vs. TFAM mRNAnon-DS:
1.00 ± 0.26; P b 0.05). In the non-DS cell line, transfection of the hsa-
miR-155-5p mimic decreased the expression of TFAM mRNA by 28%
(P b 0.01), and reduced mtDNA content by 50% (P b 0.001), in compar-
ison to controls (Fig. 2A). In the DS cell line, the hsa-miR-155-5pmimic
reduced TFAM mRNA expression by 51% in comparison to controls
(P b 0.001). The hsa-miR-155-5pmimic did not reduce mtDNA content
in the DS cell line in comparison to controls (Fig. 2A).
In both cell lines, inhibition of hsa-miR-155-5p expression by the
speciﬁc inhibitor restored TFAM mRNA levels (Fig. 2B). In addition,
mtDNA content remained unaffected after co-transfections with the
hsa-miR-155-5p speciﬁc inhibitor plus the hsa-miR-155-5p mimic
(Fig. 2B). In all cases, there were no signiﬁcant changes in cell viability
(Supplemental Table 2).
3.3. Effect of hsa-miR-155-5p onmitochondrial and cytosolic TFAM content
In non-DS ﬁbroblast cells transfected with the hsa-miR-155-5p
mimic, there was a slight 12% reduction (P b 0.05) in mitochondrial
TFAM protein levels in comparison to controls (Fig. 3A). No signiﬁcant
changes in mitochondrial TFAM levels were observed in DS ﬁbroblasts
transfected with the hsa-miR-155-5p mimic (Fig. 3A). Co-transfection
with the hsa-miR-155-5p mimic plus the speciﬁc inhibitor resulted in
no changes in mitochondrial TFAM protein levels in DS and non-DS ﬁ-
broblasts (Fig. 3B). There were no signiﬁcant changes in cytosolic
TFAM levels in DS and non-DS ﬁbroblasts transfected with the hsa-
miR-155-5pmimic (Supplemental Fig. 1).
3.4. Effect of hsa-miR-155-5p on mitochondrial content
Citrate synthase activity, an exclusive marker of the mitochondrial
matrix, is proportional to the number of viable mitochondria. In the
non-DS cell line, the hsa-miR-155-5p mimic signiﬁcantly decreased
citrate synthase activity by 38% (P b 0.001) in comparison to control
incubations (Fig. 4A). The effect of hsa-miR-155-5pmimic on citrate syn-
thase activity was abolished by co-transfections with the speciﬁc hsa-
miR-155-5p inhibitor (Fig. 4B). In contrast, the hsa-miR-155-5p mimic
exerted not signiﬁcant changes in mitochondrial citrate synthase activ-
ity in the DS cell line (Fig. 4A).
Fig. 1. Schematic representation of human TFAM showing the potential binding site for hsa-miR-155-5p (A, top). Predicted sequence interactions between TFAM and hsa-miR-155-5p, and
between themutated TFAM 3′-UTR (mutTFAM3′-UTR) and hsa-miR-155-5p (A,middle). Luciferase activities of the TFAM 3′-UTR construct inCHO-K1 cells transfectedwith hsa-miR-155-5p
mimic or speciﬁc controls (B). Luciferase activities of the mutTFAM 3′-UTR construct in CHO-K1 cells transfected with hsa-miR-155-5pmimic or speciﬁc controls (C). For each construct,
normalized luciferase activities were expressed relative to the values from control transfections (miRNA mimic negative control or miRNA mimic negative control + inhibitor negative
control). Data represent the mean ± standard deviation of three independent experiments. ***P b 0.001, (Student's t-test).
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imaging analyses were performed to determine whether the effects
of hsa-miR-155-5p on mtDNA content and citrate synthase activity
were paralleled by a decrease in the number of mitochondria. In
non-DS ﬁbroblasts, transfection of the hsa-miR-155-5pmimic caused
a 26% decrease in the number of mitochondria in comparison to con-
trols (P b 0.001; Fig. 5A). The effect of hsa-miR-155-5p mimic was
abolished when cells were transfected with the speciﬁc inhibitor of
hsa-miR-155-5p (Fig. 5A). In DS cells, transfections of the hsa-miR-Fig. 2. TFAMmRNA levels (left) and mtDNA content (right) in ﬁbroblast cell lines derived from
(A) or hsa-miR-155-5p plus the speciﬁc hsa-miR-155-5p inhibitor control (B). Data represent
***P b 0.001, (Student's t-test).155-5p mimic did not signiﬁcantly change the number of mitochon-
dria (Fig. 5B).
3.5. Hsa-miR-155 and TFAM mRNA levels in human hearts from donors
with and without Down syndrome
Recently, we reported no differences in mtDNA content and hsa-
miR-155 expression between heart tissue samples from donors
with and without Down syndrome [14]. These observations weredonors with and without DS. Fibroblast cells were transfected with hsa-miR-155-5pmimic
the mean ± SD from three independent experiments performed in triplicate. **P b 0.01,
Fig. 3. TFAM protein levels in mitochondria from ﬁbroblast cell lines derived from donors with and without DS. Fibroblast cells were transfected with hsa-miR-155-5pmimic (A) or hsa-
miR-155-5p plus the speciﬁc hsa-miR-155-5p inhibitor control (B). Data represent the mean ± SD of four independent experiments. *P b 0.05 (Student's t-test).
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mRNA. The relative expression of TFAMmRNAwas similar in heart sam-
ples from donors with and without DS (DSTFAMmRNA: 1.29 ± 0.71 rela-
tive fold vs. non-DSTFAM mRNA: 1.00 ± 0.64 relative fold; Student's t
test, P= 0.215. Fig. 6A). Further correlation analyses revealed a signiﬁ-
cant negative association between hsa-miR-155 and TFAM mRNA ex-
pression in hearts from donors without DS (Spearman's regression
coefﬁcient, rS=−0.619, P b 0.001. Fig. 6B). Similarly, therewas a signif-
icant negative association between hsa-miR-155 and TFAM mRNA ex-
pression in heart tissue samples from donors with DS (Spearman's
regression coefﬁcient, rS=−0.846, P b 0.01. Fig. 6C). Therewere no sig-
niﬁcant associations between cardiacmtDNA content and relative TFAM
mRNA expression in samples from donors with (Spearman's regression
coefﬁcient, rS =−0.080, P = 0.816) and without DS (Spearman's re-
gression coefﬁcient, rS =−0.179, P= 0.327).
4. Discussion
Mitochondrial dysfunctionmay contribute to theDSphenotype [16].
There is a paucity of reports on the role of speciﬁc miRNAs during the
regulation of TFAM expression and mitochondrial biogenesis in the DS
setting. The aim of this study was to examine whether hsa-miR-155, a
prominentmiRNA encoded by chromosome 21, regulates mitochondri-
al biogenesis through interactions with TFAM in cells from donors with
and without DS.
First, we identiﬁed a candidate binding site for hsa-miR-155-5p in
the 3′-UTR of TFAM. Loeb et al. showed that 40% of the binding interac-
tions of hsa-miR-155 with the transcriptome of activated CD4+ T cellsFig. 4.Mitochondrial citrate synthase activity inﬁbroblast cell lines derived fromdonorswith an
155-5p plus the speciﬁc hsa-miR-155-5p inhibitor control (B). Data represent the mean ± SD ooccur at sites without perfect complementary matches (i.e., non-
canonical sites), similarly to the binding site in TFAM (Fig. 1A) [30].
Next, the bioinformatics prediction was experimentally veriﬁed
through gene reporter experiments in CHO-K1 cells co-transfected
with the 3′-UTR of TFAM and hsa-miR-155-5p (Fig. 1. B). The 27% de-
crease in luciferase activity exerted by the hsa-miR-155-5pmimic is in
line with previous observations describing the impact of various
miRNAs on TFAM regulation under comparable experimental condi-
tions. For example: a) Yao et al. documented a 20% decrease in luciferase
activity for hsa-miR-200, b) Jiang et al. documented a 36%decrease in lu-
ciferase activity for hsa-miR-23b, and c) Yamamoto et al. documented a
16% in luciferase activity for hsa-miR-494 [7–9]. The speciﬁcity of the
binding site for hsa-miR-155-5p was conﬁrmed by mutating the se-
quence of the seed region in the 3′-UTR of TFAM (Fig. 1C). We also
found that transfection of hsa-miR-155-5p into ﬁbroblast cells derived
from a donor without DS induced signiﬁcant decreases in TFAMmRNA
expression and mtDNA content (Fig. 2). The transfection of hsa-miR-
155-5p also led to a signiﬁcant decrease in TFAMmRNA levels in ﬁbro-
blasts from a donorwith DS; however, mtDNA content remained essen-
tially unchanged (Fig. 2). Under standard cell culture conditions, the
average mtDNA content in DS ﬁbroblasts was 64% lower than the
mtDNA content in non-DS ﬁbroblasts (P b 0.001. Fig. 2). It appears
that in DS cells, the downregulation of TFAM mRNA expression by hsa-
miR-155-5p is not followed by signiﬁcant reductions in mtDNA content.
It is possible that in the DS setting, further reductions inmtDNA content
beyond a critical threshold (i.e.,MT-ND1/18S ratio: 0.08 ± 0.03) would
not be tolerated without a compromise in cellular viability. This notion
is supported by the following ﬁndings: a) transfection of hsa-miR-155-dwithoutDS. Fibroblast cellswere transfectedwith hsa-miR-155-5pmimic (A) or hsa-miR-
f four independent experiments. ***P b 0.001, (Student's t-test).
Fig. 5.Mitochondrial content inﬁbroblast cell lines derived fromdonorswithout (A) andwithDS (B). Fibroblast cellswere transfectedwith hsa-miR-155-5pmimic (toppanels) or hsa-miR-
155-5p plus the speciﬁc hsa-miR-155-5p inhibitor control (bottom panels). Representative ﬂuorescencemicroscopy images are shown in the left and corresponding graphs in the right. For
each condition, the graphs show data from ten cells per experiment, and from three independent experiments. Each symbol depicts the number ofmitochondria per squaremicrometer of
a whole single cell. ***P b 0.001, (Student's t-test).
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tein levels in non-DS cells, but no effect was apparent in the DS cells
(Fig. 3), b) mitochondrial citrate synthase activity was reduced by hsa-
miR-155-5p in non-DS cells but not in non-DS cells (Fig. 4), and c) hsa-
miR-155-5p reduced the number of mitochondria in non-DS cells but
the miRNA mimic exerted no signiﬁcant effect on the number of mito-
chondria in DS cells (Fig. 5). Together, these results suggest that hsa-
miR-155-5p is a negative regulator of TFAM expression and mitochon-
drial biogenesis in diploid cells. As noted, there is an increasing number
of reports pinpointing speciﬁc miRNAs that regulate TFAM in various
cellular contexts. Loeb et al. postulated that combinations of miRNAs
binding through canonical and non-canonical sites may afford a wide
spectrum of gene regulation with major biological consequences [30].
In line with this notion, it appears that the relatively modest regulation
of TFAM expression by hsa-miR-155-5p through a non-canonicalinteraction triggers important changes in mitochondrial parameters
(e.g., mtDNA and mitochondrial content). However, it is also possible
that the observed effects may result from additional interactions be-
tween hsa-miR-155-5p and transcriptional factors involved in mito-
chondrial biogenesis. For example, PGC-1a is a central inducer of
mitochondrial biogenesis in cells, and the expression of PGC-1a is re-
duced in brown fat cells that overexpress miR-155 [31]. Our results
also suggest that hsa-miR-155-5p interacts with TFAM in trisomic cells;
however, the absence of signiﬁcant changes in speciﬁc mitochondrial
parameters (e.g., mtDNA content, citrate synthase activity, and number
of mitochondria) points towards the involvement of additional factors
during the control of mitochondrial biogenesis in the DS setting.
Widespread mitochondrial dysfunction in DS has been associated
with the development of cardiac alterations in structure and function
in some individuals with DS [32]. In this study, we identiﬁed signiﬁcant
Fig. 6. Cardiac TFAMmRNA expression in samples from donors with (n= 11) andwithout DS (n= 32). Each symbol depicts the average of individual samples. Samples were analyzed in
triplicates (A). Linear regression analysis of cardiac hsa-miR-155 expression versus TFAMmRNA expression in samples from donors without (B) and with DS (C).
1426 A. Quiñones-Lombraña, J.G. Blanco / Biochimica et Biophysica Acta 1852 (2015) 1420–1427associations between cardiac hsa-miR-155 and TFAM mRNA expression
in heart tissue samples from donors with and without DS, with no sig-
niﬁcant alterations in mtDNA content (Fig. 6). Although these pilot ob-
servations are limited by the relatively small number of samples from
donors with DS, the extent of the linear associations in heart tissue pro-
vides additional support for a distinct functional link between hsa-miR-
155-5p and TFAM. Donor's age is a relevant co-variable when analyzing
changes inmtDNA content in human tissues [22]. For example, we have
reported a more pronounced decline in cardiac mtDNA content with
aging in samples from donors without DS than in samples from donors
with DS [14]. The current limitations in sample size precluded us from
examining the combined impact of donor's age, hsa-miR-155-5p and
TFAM expression on cardiac mtDNA through multiple linear regression
analysis.
Our ﬁndings suggest a novel function for hsa-miR-155-5p during the
control of TFAM expression and mitochondrial biogenesis in diploid
cells. In contrast, it appears that the hsa-miR-155-5p-TFAM interaction
does not impact the biogenesis ofmitochondria in cells with trisomy 21.
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